Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTS-519 Insert for Onychomycosis
NCT02798380Phase 2Completed
- Sponsor
- Hallux Inc.
- Start
- Jul 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Terbinafine in onychomycosis, sponsored by Hallux Inc. Primary endpoint: Treatment Related Adverse Events at 48 weeks. Started Jul 2016; status: completed.
02
Drugs
Terbinafine
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT02798380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02798380.